Ani Pharmaceuticals [ANIP] vs Perrigo Company plc [PRGO] Detailed Stock Comparison

Ani Pharmaceuticals Inc.

NASDAQ
Loading...

Perrigo Company plc

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Ani Pharmaceuticals Inc. wins in 13 metrics, Perrigo Company plc wins in 7 metrics, with 0 ties. Ani Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Ani Pharmaceuticals Inc. Perrigo Company plc Better
P/E Ratio (TTM) 24.08 2,818.00 Ani Pharmaceuticals Inc.
Price-to-Book Ratio 3.10 0.55 Perrigo Company plc
Debt-to-Equity Ratio 116.19 131.16 Ani Pharmaceuticals Inc.
PEG Ratio -0.07 0.91 Perrigo Company plc
EV/EBITDA 11.46 7.26 Perrigo Company plc
Profit Margin (TTM) 8.87% -33.51% Ani Pharmaceuticals Inc.
Operating Margin (TTM) 11.99% 10.20% Ani Pharmaceuticals Inc.
EBITDA Margin (TTM) 11.99% 10.20% Ani Pharmaceuticals Inc.
Return on Equity 16.16% -38.66% Ani Pharmaceuticals Inc.
Return on Assets (TTM) 3.82% 2.35% Ani Pharmaceuticals Inc.
Free Cash Flow (TTM) $150.90M $145.10M Ani Pharmaceuticals Inc.
Dividend Yield N/A 9.92% N/A
1-Year Return 33.70% -58.72% Ani Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 2.06 0.38 Perrigo Company plc
Enterprise Value $2.00B $4.93B Perrigo Company plc
EV/Revenue Ratio 2.27 1.16 Perrigo Company plc
Gross Profit Margin (TTM) 59.42% 32.64% Ani Pharmaceuticals Inc.
Revenue per Share (TTM) $44 $31 Ani Pharmaceuticals Inc.
Earnings per Share (Diluted) $3.32 $-10.12 Ani Pharmaceuticals Inc.
Beta (Stock Volatility) 0.44 0.49 Ani Pharmaceuticals Inc.
Short % of Float 19.22% 18.67% Perrigo Company plc

Ani Pharmaceuticals Inc. vs Perrigo Company plc Stock Performance Analysis

Loading Price Chart...

ANIP
PRGO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Ani Pharmaceuticals Inc.0.78%-7.99%-8.61%-1.14%-9.00%-4.08%
Perrigo Company plc0.00%-6.27%-8.17%-8.17%-25.07%-24.69%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Ani Pharmaceuticals Inc.33.70%63.56%128.36%43.87%-27.55%-28.50%
Perrigo Company plc-58.72%-66.51%-76.52%-88.64%-86.89%-34.38%

Performance & Financial Health Analysis: Ani Pharmaceuticals Inc. vs Perrigo Company plc

MetricANIPPRGO
Market Information
Market Cap i$1.78B$1.61B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i380,5352,169,621
90 Day Avg. Volume i370,6183,503,450
Last Close$75.23$10.46
52 Week Range$59.61 - $99.50$9.23 - $28.44
% from 52W High-24.39%-63.22%
All-Time High$450.00 (May 29, 2000)$215.73 (Apr 06, 2015)
% from All-Time High-83.28%-95.15%
Growth Metrics
Quarterly Revenue Growth0.30%-0.03%
Quarterly Earnings Growth0.30%-0.03%
Financial Health
Profit Margin (TTM) i0.09%-0.34%
Operating Margin (TTM) i0.12%0.10%
Return on Equity (TTM) i0.16%-0.39%
Debt to Equity (MRQ) i116.19131.16
Cash & Liquidity
Book Value per Share (MRQ)$25.81$21.33
Cash per Share (MRQ)$14.12$3.86
Operating Cash Flow (TTM) i$185.22M$238.50M
Levered Free Cash Flow (TTM) i$119.42M$28.33M
Dividends
Last 12-Month Dividend Yield iN/A9.92%
Last 12-Month Dividend iN/A$1.16

Valuation & Enterprise Metrics Analysis: Ani Pharmaceuticals Inc. vs Perrigo Company plc

MetricANIP (Apr 24, 2026)PRGO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i24.082,818.00
Forward P/E i7.554.93
PEG Ratio i-0.070.91
Price to Sales (TTM) i2.060.38
Price to Book (MRQ) i3.100.55
Market Capitalization
Market Capitalization i$1.78B$1.61B
Enterprise Value i$2.00B$4.93B
Enterprise Value Metrics
Enterprise to Revenue i2.271.16
Enterprise to EBITDA i11.467.26
Risk & Other Metrics
Beta i0.440.49
Book Value per Share (MRQ) i$25.81$21.33

Financial Statements Comparison: Ani Pharmaceuticals Inc. vs Perrigo Company plc

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricANIP (2025)PRGO (2025)
Revenue/Sales i883.37M4.25B
Cost of Goods Sold i341.31M2.76B
COGS % of Revenue i38.6%64.9%
Gross Profit i542.06M1.49B
Gross Margin i61.4%35.1%
Research & Development i51.66M95.40M
Operating Income (EBIT) i81.23M312.80M
Operating Margin i9.2%7.4%
EBITDA i174.58M637.10M
EBITDA Margin i19.8%15.0%
Pre-Tax Income i95.79M-1.30B
Pre-Tax Income % of Revenue i10.8%-30.5%
Income Tax i17.45M104.40M
Income Tax % of Revenue i2.0%2.5%
Net Income (Profit) i78.34M-1.43B
Profit Margin i8.9%-33.5%

Balance Sheet & Liquidity Metrics

MetricANIP (2025)PRGO (2025)
Cash & Equivalents i285.59M531.60M
Total Current Assets i753.12M2.80B
Total Current Assets % of Revenue i85.3%65.8%
Total Current Liabilities i278.11M1.01B
Total Current Liabilities % of Revenue i31.5%23.8%
Long-Term Debt i599.77M3.60B
Long-Term Debt % of Revenue i67.9%84.7%
Total Shareholders Equity i540.72M2.94B
Retained Earnings i-23.10M-3.68B
Retained Earnings % of Revenue i-2.6%-86.5%
Property, Plant & Equipment i650,000167.80M

Cash Flow Statement Comparison

MetricANIP (2025)PRGO (2025)
Operating Cash Flow i139.39M-1.06B
Operating Cash Flow % of Revenue i15.8%-24.9%
Capital Expenditures i-13.84M-93.40M
Free Cash Flow i150.90M145.10M
FCF Margin i17.1%3.4%
Debt Repayment i-10.16M-34.80M
Common Stock Repurchase i-12.21MN/A

Short Interest & Institutional Ownership Analysis

MetricANIPPRGO
Shares Short i3.58M16.69M
Short Ratio i9.943.99
Short % of Float i19.22%18.67%
Shares Outstanding i22.49M137.62M
Float Shares i19.34M136.81M
% Held by Insiders i7.37%0.41%
% Held by Institutions i99.81%115.48%
% Held by Public i-7.18%-15.89%

Dividend Analysis & Yield Comparison: Ani Pharmaceuticals Inc. vs Perrigo Company plc

MetricANIPPRGO
Last 12-Month Dividend iN/A$1.16
Last 12-Month Dividend Yield iN/A9.92%
3-Year Avg Annual Dividend iN/A$1.12
3-Year Avg Dividend Yield iN/A1.09%
3-Year Total Dividends iN/A$3.36
Ex-Dividend DateN/AMar 02, 2026